Posted by Michael Wonder on 08 Aug 2025
FDA approves expanded indication for Avtozma (tocilizumab-anoh) intravenous formulation in cytokine release syndrome
6 August 2025 - Approval of Avtozma (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and paediatric patients aged 2 years and older with cytokine release syndrome.
Celltrion today announced that the US FDA has approved an expanded indication of the intravenous formulation of Avtozma (tocilizumab-anoh) to include the treatment of cytokine release syndrome in adults and paediatric patients aged 2 years and older. Following FDA approval of the additional indication for cytokine release syndrome, Avtozma IV now aligns with all indications approved for Actemra IV in the US.
